OCT 01, 2015 7:30 AM PDT

A Case Study for Immunotherapies and Targeted Therapies

Speaker

Abstract

Melanoma, a cancer of pigment-producing cells, accounts for nearly 200,000 new cases of cancer reported each year worldwide. It is the deadliest skin cancer. Alarmingly, in the U.S., the incidence has tripled over the last three decades, and the death rate has increased at a time when mortality for other common cancers has declined. If caught early, melanoma can be successfully treated by surgery, while those diagnosed with widespread metastatic disease (Stage IV) have a median survival of less than one year. Eight new treatments have been approved since 2011 that have revolutionized the field, provided new hope for patients, and showcased melanoma as a case study for all of oncology. These therapies fall into two classes: 1) targeted therapies that block growth-promoting pathways in melanomas with activating mutations in BRAF (vemurafenib, dabrafenib, and trametinib); and 2) immunotherapies that target the “brakes” on the immune system including the checkpoint inhibitor antibodies to CTLA-4 (ipilimumab) and PD-1 (pembrolizumab and nivolumab). Despite the benefits that these FDA- and European Commission-approved treatments offer, there is a significant need for new therapeutic approaches to overcome primary and treatment-emergent resistance and lead to ever improved outcomes for patients. Through research and the engagement of all stakeholders, including academia, the pharmaceutical industry, government, patients, entrepreneurs and donors, the melanoma research community will continue to produce cutting-edge therapies whose benefits will extend beyond melanoma and impact other cancers as well.


Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
APR 01, 2021 8:00 AM PDT
C.E. CREDITS
APR 01, 2021 8:00 AM PDT
Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
OCT 27, 2021 8:00 AM PDT
C.E. CREDITS
OCT 27, 2021 8:00 AM PDT
Date: October 27, 2021 Time: 8:00am (PDT), 11:00am (EDT) Learn about how brightfield images can take your flow cytometry data to the next level. Join Dr. Cora Chadick, Technical Director, as...
JUN 24, 2021 10:00 AM PDT
C.E. CREDITS
JUN 24, 2021 10:00 AM PDT
Date: June 24, 2021 Time: 10:00am PDT The Chan Zuckerberg Initiative (CZI) was founded to help solve some of society’s toughest challenges— from eradicating disease and improving...
OCT 01, 2015 7:30 AM PDT

A Case Study for Immunotherapies and Targeted Therapies


Specialty

Research And Development

Gene Expression

Dna

Big Data

Cancer Research

Tumor

Biomarkers

Cancer

Earth Science

Oncology

University

Gene Sequencing

Drug Discovery

Mass Cytometry

Cell Culture

Geography

Asia50%

Europe50%

Registration Source

Website Visitors100%

Job Title

Student50%

Medical Laboratory Technician50%

Organization

Manufacturer - Other50%

Academic Institution50%


Show Resources
Loading Comments...
Show Resources